Exploring clinical profile and treatment outcome differences based on baseline smoking and alcohol co‐use status among individuals initiating medication for opioid use disorder treatment

Documents similaires

• Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder
  par: Payel J. Roy, et autres
  Publié: (2025)
• Evaluating the optimal duration of medication treatment for opioid use disorder
  par: Corey J. Hayes, et autres
  Publié: (2026)
• Empirically contrasting urine drug screening‐based opioid use disorder treatment outcome definitions
  par: Laura Brandt, et autres
  Publié: (2024)
• Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals
  par: Jake R. Morgan, et autres
  Publié: (2024)
• A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine
  par: Charles Deng, et autres
  Publié: (2025)